Abstract:Previous investigations have demonstrated that endogenous inhibitors of nitric oxide synthase (NOS), such as asymmetric dimethylarginine (ADMA), contribute importantly to endothelial dysfunction, and that fenofibrate has a protective effect on the endothelium in rats treated with low-density lipoprotein (LDL) by reducing ADMA levels. In the present study, we explored further the possible mechanism underlying inhibition of ADMA generation by fenofibrate in cultured human umbilical vein endothelial cells (HUVECs). Endothelial injury was induced in cultured HUVECs by incubation with oxidative LDL (ox-LDL) and the levels of ADMA, lactate dehydrogenase (LDH), NO and tumour necrosis factor-alpha (TNF-alpha) in the conditioned medium were measured. Cell viability and the activity of dimethylarginine dimethylaminohydrolase (DDAH) and nuclear factor-kappa B (NF-kappa B) in the cultured HUVECs were also determined. Incubation of HUVECs with ox-LDL (100 mu g/ml) for 24 h markedly elevated ADMA, LDH and TNF-alpha in the conditioned medium and significantly 886, a specific peroxisome proliferator-activated receptor-a (PPAR alpha) antagonist. The present results suggest that feno-fibrate inhibits ox-LDL-induced endothelial cell damage by decreasing ADMA and increasing DDAH activity, and the protective effects of fenofibrate on endothelial cells may be related to reduction of NF-kappa B activity by activation of the PPARa receptor.increased the activity of NF-kappa B, concomitantly with a significant decrease in the activity of DDAH and the content of NO. Pretreatment with fenofibrate ( 3, 10 or 30 mu M) significantly inhibited the increases in ADMA, LDH and TNF-alpha, attenuated the decreased levels of NO and the decreased activity of DDAH and prevented the activation of NF-kappa B. Similar effects were observed in the presence of pyrrolidine dithiocarbamate (PDTC, 10 mu M), an antagonist of NF-kappa B. The beneficial effects of fenofibrate on cultured endothelial cells were abolished by MK-886, a specific peroxisome proliferator-activated receptor-a (PPAR alpha) antagonist. The present results suggest that feno-fibrate inhibits ox-LDL-induced endothelial cell damage by decreasing ADMA and increasing DDAH activity, and the protective effects of fenofibrate on endothelial cells may be related to reduction of NF-kappa B activity by activation of the PPARa receptor.

Fenofibrate Decreases Asymmetric Dimethylarginine Level in Cultured Endothelial Cells by Inhibiting NF-κB Activity

Effect of Fenofibrate on LDL-induced Endothelial Dysfunction in Rats

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]

Fenofibrate Inhibits Tumor Necrosis Factor-Alpha-induced Expression of CD40 and Matrix Metalloproteinase in Human Vascular Endothelial Cells.

Fenofibrate Partly Prevents Oxidized-Low Density Lipoprotein Induced Immune Maturation of Human Monocyte-Derived Dendritic Cell

PPARα Agonist Stimulated Angiogenesis by Improving Endothelial Precursor Cell Function Via a NLRP3 Inflammasome Pathway

Effect of Fenofibrate on the Level of Asymmetric Dimethylarginine in Individuals with Hypertriglyceridemia

The Protective Effect of Fenofibrate Against TNF-α-Induced CD40 Expression through SIRT1-Mediated Deacetylation of NF-κB in Endothelial Cells

Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia

Effect of Fenofibrate on Adiponectin Gene Expression and Endothelial Function in Diabetic Rats

Abstract 5221: Plasma Levels of Tetrahydrobiopterin and Endothelial Function Were Improved by Fenofibrate Treatment in Patients with Hypertriglyceridemia

Ppar Alpha Activator Fenofibrate Modulates Angiotensin Ii-Induced Inflammatory Responses in Vascular Smooth Muscle Cells Via the Tlr4-Dependent Signaling Pathway

Fenofibrate re-couples endothelial nitric oxide synthase by restoring the level of tetrahydrobiopterin in human umbilical vein endothelial cells

Fenoﬁbrate suppresses cellular metabolic memory of high glucose in diabetic retinopathy via a sirtuin 1-dependent signalling pathway

Fenofibrate Reduces Tumor Necrosis Factor-Α Serum Concentration and Adipocyte Secretion of Hypercholesterolemic Rabbits

Fenofibrate Enhances Cd36 Mediated Endocytic Uptake and Degradation of Oxidized Low Density Lipoprotein in Adipocytes from Hypercholesterolemia Rabbit

Fenofibrate Ameliorates Cardiac Hypertrophy by Activation of Peroxisome Proliferator-Activated Receptor-Α Partly Via Preventing P65-Nfκb Binding to NFATc4.

Fenofibrate Exerts Protective Effects In Diabetic Retinopathy Via Inhibition Of The Angptl3 Pathway

Fenofibrate Ameliorates Retinal Pigment Epithelium Injury Induced by Excessive Fat Through Upregulation of PI3K/AKT Signaling

Fenofibrate Inhibits Thrombogenic and Fibrinolytic Factors Expression in Cultured Adipocytes from Rabbits